Prospects for a group A streptococcal vaccine

Rationale, feasibility, and obstacles - Report of a National Institute of Allergy and Infectious Diseases workshop

Alan L. Bisno, Fran A. Rubin, P. Patrick Cleary, James Dale

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Infections due to group A streptococci (GAS) represent a public health problem of major proportions in both developing and developed countries. Currently available methods of prevention are either inadequate or ineffective, as attested to by the morbidity and mortality associated with this ubiquitous pathogen worldwide. Advances in molecular biology have shed new light on the pathogenesis of GAS infections and have identified a number of virulence factors as potential vaccine targets. Therefore, the National Institute of Allergy and Infectious Diseases convened an expert workshop in March 2004 to review the available data and to explore the microbiologic, immunologic, epidemiologic, and economic issues involved in development and implementation of a safe and effective GAS vaccine. Participants included scientists and clinicians involved in GAS research, as well as representatives of United States federal agencies (Centers for Disease Control and Prevention, Food and Drug Administration, Department of Defense, and National Institute of Allergy and Infectious Diseases), the World Health Organization, and the pharmaceutical industry. This report summarizes the deliberations of the workshop.

Original languageEnglish (US)
Pages (from-to)1150-1156
Number of pages7
JournalClinical Infectious Diseases
Volume41
Issue number8
DOIs
StatePublished - Oct 15 2005

Fingerprint

Streptococcal Vaccines
National Institute of Allergy and Infectious Diseases (U.S.)
Streptococcus
Education
Vaccines
Drug Industry
Virulence Factors
United States Food and Drug Administration
Centers for Disease Control and Prevention (U.S.)
Infection
Developed Countries
Developing Countries
Molecular Biology
Public Health
Economics
Morbidity
Mortality
Research

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Prospects for a group A streptococcal vaccine : Rationale, feasibility, and obstacles - Report of a National Institute of Allergy and Infectious Diseases workshop. / Bisno, Alan L.; Rubin, Fran A.; Cleary, P. Patrick; Dale, James.

In: Clinical Infectious Diseases, Vol. 41, No. 8, 15.10.2005, p. 1150-1156.

Research output: Contribution to journalArticle

@article{fbad49a650f143df8f1f8f70a404cf04,
title = "Prospects for a group A streptococcal vaccine: Rationale, feasibility, and obstacles - Report of a National Institute of Allergy and Infectious Diseases workshop",
abstract = "Infections due to group A streptococci (GAS) represent a public health problem of major proportions in both developing and developed countries. Currently available methods of prevention are either inadequate or ineffective, as attested to by the morbidity and mortality associated with this ubiquitous pathogen worldwide. Advances in molecular biology have shed new light on the pathogenesis of GAS infections and have identified a number of virulence factors as potential vaccine targets. Therefore, the National Institute of Allergy and Infectious Diseases convened an expert workshop in March 2004 to review the available data and to explore the microbiologic, immunologic, epidemiologic, and economic issues involved in development and implementation of a safe and effective GAS vaccine. Participants included scientists and clinicians involved in GAS research, as well as representatives of United States federal agencies (Centers for Disease Control and Prevention, Food and Drug Administration, Department of Defense, and National Institute of Allergy and Infectious Diseases), the World Health Organization, and the pharmaceutical industry. This report summarizes the deliberations of the workshop.",
author = "Bisno, {Alan L.} and Rubin, {Fran A.} and Cleary, {P. Patrick} and James Dale",
year = "2005",
month = "10",
day = "15",
doi = "10.1086/444505",
language = "English (US)",
volume = "41",
pages = "1150--1156",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Prospects for a group A streptococcal vaccine

T2 - Rationale, feasibility, and obstacles - Report of a National Institute of Allergy and Infectious Diseases workshop

AU - Bisno, Alan L.

AU - Rubin, Fran A.

AU - Cleary, P. Patrick

AU - Dale, James

PY - 2005/10/15

Y1 - 2005/10/15

N2 - Infections due to group A streptococci (GAS) represent a public health problem of major proportions in both developing and developed countries. Currently available methods of prevention are either inadequate or ineffective, as attested to by the morbidity and mortality associated with this ubiquitous pathogen worldwide. Advances in molecular biology have shed new light on the pathogenesis of GAS infections and have identified a number of virulence factors as potential vaccine targets. Therefore, the National Institute of Allergy and Infectious Diseases convened an expert workshop in March 2004 to review the available data and to explore the microbiologic, immunologic, epidemiologic, and economic issues involved in development and implementation of a safe and effective GAS vaccine. Participants included scientists and clinicians involved in GAS research, as well as representatives of United States federal agencies (Centers for Disease Control and Prevention, Food and Drug Administration, Department of Defense, and National Institute of Allergy and Infectious Diseases), the World Health Organization, and the pharmaceutical industry. This report summarizes the deliberations of the workshop.

AB - Infections due to group A streptococci (GAS) represent a public health problem of major proportions in both developing and developed countries. Currently available methods of prevention are either inadequate or ineffective, as attested to by the morbidity and mortality associated with this ubiquitous pathogen worldwide. Advances in molecular biology have shed new light on the pathogenesis of GAS infections and have identified a number of virulence factors as potential vaccine targets. Therefore, the National Institute of Allergy and Infectious Diseases convened an expert workshop in March 2004 to review the available data and to explore the microbiologic, immunologic, epidemiologic, and economic issues involved in development and implementation of a safe and effective GAS vaccine. Participants included scientists and clinicians involved in GAS research, as well as representatives of United States federal agencies (Centers for Disease Control and Prevention, Food and Drug Administration, Department of Defense, and National Institute of Allergy and Infectious Diseases), the World Health Organization, and the pharmaceutical industry. This report summarizes the deliberations of the workshop.

UR - http://www.scopus.com/inward/record.url?scp=26444527988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26444527988&partnerID=8YFLogxK

U2 - 10.1086/444505

DO - 10.1086/444505

M3 - Article

VL - 41

SP - 1150

EP - 1156

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 8

ER -